Syngene International posts Q4 FY25 consolidated profit at Rs. 183.3 Cr
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The 27 greenfield labs across the country ensure timely and accurate reporting
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
This unit will focus on the manufacturing of health and wellness equipment
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Subscribe To Our Newsletter & Stay Updated